BR0212469A - Método para multiplicação de vìrus em cultura de célula - Google Patents

Método para multiplicação de vìrus em cultura de célula

Info

Publication number
BR0212469A
BR0212469A BR0212469-6A BR0212469A BR0212469A BR 0212469 A BR0212469 A BR 0212469A BR 0212469 A BR0212469 A BR 0212469A BR 0212469 A BR0212469 A BR 0212469A
Authority
BR
Brazil
Prior art keywords
cell culture
multiplication
viruses
cells
virus multiplication
Prior art date
Application number
BR0212469-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Juergen Vorlop
Christian Frech
Holger Luebben
Jens-Peter Gregersen
Original Assignee
Chiron Behring Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring Gmbh & Co filed Critical Chiron Behring Gmbh & Co
Publication of BR0212469A publication Critical patent/BR0212469A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12051Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0212469-6A 2001-09-12 2002-09-11 Método para multiplicação de vìrus em cultura de célula BR0212469A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
PCT/EP2002/010207 WO2003023025A1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Publications (1)

Publication Number Publication Date
BR0212469A true BR0212469A (pt) 2004-08-24

Family

ID=7698761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212469-6A BR0212469A (pt) 2001-09-12 2002-09-11 Método para multiplicação de vìrus em cultura de célula

Country Status (16)

Country Link
US (1) US20050118698A1 (https=)
EP (1) EP1427817B1 (https=)
JP (2) JP2005502357A (https=)
KR (1) KR100968141B1 (https=)
AT (1) ATE466932T1 (https=)
AU (1) AU2002338666B2 (https=)
BR (1) BR0212469A (https=)
CA (1) CA2456561A1 (https=)
CY (1) CY1110716T1 (https=)
DE (2) DE10144903A1 (https=)
DK (1) DK1427817T3 (https=)
ES (1) ES2345606T3 (https=)
NZ (1) NZ532203A (https=)
PT (1) PT1427817E (https=)
SI (1) SI1427817T1 (https=)
WO (1) WO2003023025A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551640A (en) * 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
CA2627971A1 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) * 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
RU2547587C2 (ru) 2008-09-24 2015-04-10 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
CN102741399A (zh) * 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2011138682A2 (en) 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
PH12013501708B1 (en) * 2011-02-17 2018-08-03 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
RU2599496C2 (ru) 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
AU2013306080B2 (en) * 2012-08-24 2019-01-31 Global Life Sciences Solutions Usa Llc Virus purification and formulation process
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
ID20581A (id) * 1996-10-18 1999-01-21 Res Fnd For Micbial Diseases O Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
JP4698112B2 (ja) * 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法

Also Published As

Publication number Publication date
NZ532203A (en) 2005-04-29
US20050118698A1 (en) 2005-06-02
HK1062029A1 (zh) 2004-10-15
PT1427817E (pt) 2010-08-10
EP1427817A1 (de) 2004-06-16
ES2345606T3 (es) 2010-09-28
DE50214416D1 (de) 2010-06-17
SI1427817T1 (sl) 2010-08-31
JP2010246559A (ja) 2010-11-04
DE10144903A1 (de) 2003-03-27
CA2456561A1 (en) 2003-03-20
ATE466932T1 (de) 2010-05-15
CY1110716T1 (el) 2015-06-10
AU2002338666B2 (en) 2008-11-20
WO2003023025A1 (de) 2003-03-20
KR20050027164A (ko) 2005-03-17
EP1427817B1 (de) 2010-05-05
JP2005502357A (ja) 2005-01-27
DK1427817T3 (da) 2010-08-23
KR100968141B1 (ko) 2010-07-06

Similar Documents

Publication Publication Date Title
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
WO2020198509A3 (en) Modified oligonucleotides with increased stability
BR0212470A (pt) Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck
DK0891420T4 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
DE60132770D1 (de) Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen
DE602004024285D1 (de) System auf mikrochipbasis zur hiv-diagnostik
PL1835937T3 (pl) Kompozycje i sposoby leczenia infekcji wirusowej
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
IL292053A (en) Compositions, methods and kits for biological sample and rna stabilization
DE60132443D1 (de) In lebenden zielzellen
EP1862537A4 (en) COMPOUNDS CULTIVATABLE CELLS WITHOUT ANIMALS, METHODS FOR THEIR REALIZATION, METHOD FOR PRODUCING VIRUSES USING THE CELL LINE AND IMPACT PRODUCTION PROCESS
WO2005092924A3 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
PH12022553394A1 (en) Conjugate of double-stranded sirna analogue
BR0308736A (pt) Células de pulmão de rato cotton para cultura de vìrus
WO2004031209A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
EA200101228A1 (ru) ИСПОЛЬЗОВАНИЕ АНТИТЕЛ, УЗНАЮЩИХ РЕЦЕПТОР ИНТЕРЛЕЙКИН-2, ДЛЯ ПРЕДУПРЕЖДЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСАМИ СПИДа

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHIRON BEHRING GMBH AND CO. KG (DE)

Free format text: NOME ALTERADO DE: CHIRON BEHRING GMBH AND CO.

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH AND CO. KG

Free format text: NOME ALTERADO DE: CHIRON BEHRING GMBH AND CO. KG

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH (DE)

Free format text: NOME ALTERADO DE: NOVARTIS VACCINES AND DIAGNOSTICS GMBH AND CO. KG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2271 DE 15/07/2014.